Enhertu®

 

 

Active substance

 

trastuzumab deruxtecan

Holder

Daiichi Sankyo Belgium N.V.-S.A

Status

Closed

Indication

adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens

Public documents 

Approbation

Approbation amendment 1
Approbation amendment 2

Information for the patient

Information for the patient - amendment 1
Information for the patient - amendment 2
Informed consent

Informed consent - amendment 1

  Informed consent - amendment 2

Last update

22/06/2023

Last updated on 13/02/2024